1. 264TiPENGOT-ov43/KEYLYNK-001: A phase III trial of pembrolizumab plus chemotherapy with olaparib maintenance for first-line treatment of BRCA¬-nonmutated advanced epithelial ovarian cancer. (24th November 2019) Authors: Fujiwara, K; Vergote, I B; Sehouli, J; Salutari, V; Zola, P; Madry, R; Wenham, R M; Korach, J; Pautier, P; Cibula, D; Lheureux, S; Hasegawa, K; Kim, B-G; Lai, C-H; Gonzalez-Martinez, A; Liu, Q; Keefe, S M; Puglisi, M; Topuz, S Journal: Annals of oncology Issue: Volume 30(2019)Supplement 9 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗